Drilion et al. studied the efficacy of crizotinib in 69 patients with NSCLC harboring a MET 14 exon alteration and showed plasma-derived ctDNA assays can also detect MET exon 14 alterations in NSCLC patients [54]. Here, MET is linked to non-small cell lung carcinoma.